Literature DB >> 18807220

Immunogenicity of a cholera toxin B subunit Porphyromonas gingivalis fimbrial antigen fusion protein expressed in E. coli.

Tae-Geum Kim1, Nguyen-Xuan Huy, Mi-Young Kim, Dong-Keun Jeong, Yong-Suk Jang, Moon-Sik Yang, William H R Langridge, Jin-Yong Lee.   

Abstract

The gram-negative anaerobic oral bacterium Porphyromonas gingivalis initiates periodontal disease through fimbrial attachment to saliva-coated oral surfaces. To study the effects of immunomodulation on enhancement of subunit vaccination, the expression in E. coli and immunogenicity of P. gingivalis fimbrial protein (FimA) linked to the C-terminus of the cholera toxin B subunit (CTB) were investigated. Complementary DNAs encoding the P. gingivalis 381 fimbrillin protein sequence FimA1 (amino acid residues 1-200) and FimA2 (amino acid residues 201-337) were cloned into an E. coli expression vector downstream of a cDNA fragment encoding the immunostimulatory CTB. CTB-FimA1 and CTB-FimA2 fusion proteins synthesized in E. coli BL21 (DE3) cells were purified under denaturing conditions by Ni2+-NTA affinity column chromatography. Renaturation of the CTB-FimA1 and CTB-FimA2 fusion proteins, permitted identification of CTB-FimA pentamers and restored CTB binding activity to GM1-ganglioside to provide a biologically active CTB-FimA fusion protein. Mice orally inoculated with purified CTB-FimA1 or CTB-FimA2 fusion proteins generated measurable FimA1 and FimA2 IgG antibody titers, while no serum fimbrial IgG antibodies were detected when mice were inoculated with FimA1 or FimA2 proteins alone. Immunoblot analysis confirmed that sera from mice immunized with CTB linked to FimA1 or FimA2 contained antibodies specific for P. gingivalis fimbrial proteins. In addition, mice immunized with FimA2 or CTB-FimA2 generated measurable intestinal IgA titers indicating the presence of fimbrial antibody class switching. Further, mice orally immunized with CTB-FimA1 generated higher IgA antibody titers than mice inoculated with FimA1 alone. The experimental data show that the immunostimulatory molecule CTB enhances B cell-mediated immunity against linked P. gingivalis FimA fusion proteins, in comparison to immunization with FimA protein alone. Thus, linkage of CTB to P. gingivalis fimbrial antigens can increase subunit vaccine immunogenicity to provide enhanced protection against periodontal disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807220     DOI: 10.1007/s12033-008-9102-3

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  30 in total

1.  Fimbriae of Porphyromonas gingivalis induce opsonic antibodies that significantly enhance phagocytosis and killing by human polymorphonuclear leukocytes.

Authors:  Q Fan; T Sims; H Sojar; R Genco; R C Page
Journal:  Oral Microbiol Immunol       Date:  2001-06

Review 2.  The importance of fimbriae in the virulence and ecology of some oral bacteria.

Authors:  S Hamada; A Amano; S Kimura; I Nakagawa; S Kawabata; I Morisaki
Journal:  Oral Microbiol Immunol       Date:  1998-06

3.  Role of the carboxyl-terminal region of Porphyromonas gingivalis fimbrillin in binding to salivary proteins.

Authors:  H Nagata; A Sharma; H T Sojar; A Amano; M J Levine; R J Genco
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

4.  Role of fimbriae in Porphyromonas gingivalis invasion of gingival epithelial cells.

Authors:  A Weinberg; C M Belton; Y Park; R J Lamont
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

Review 5.  Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment.

Authors:  W J Loesche; N S Grossman
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Characterization of biologically active cell surface components of a periodontal pathogen. The roles of major and minor fimbriae of Porphyromonas gingivalis.

Authors:  Toshio Umemoto; Nobushiro Hamada
Journal:  J Periodontol       Date:  2003-01       Impact factor: 6.993

7.  Fimbriated Porphyromonas gingivalis is more efficient than fimbria-deficient P. gingivalis in entering human dendritic cells in vitro and induces an inflammatory Th1 effector response.

Authors:  Ravi Jotwani; Christopher W Cutler
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

8.  Intracellular signaling and cytokine induction upon interactions of Porphyromonas gingivalis fimbriae with pattern-recognition receptors.

Authors:  George Hajishengallis; Hakimuddin Sojar; Robert J Genco; Ernesto DeNardin
Journal:  Immunol Invest       Date:  2004-05       Impact factor: 3.657

9.  Purification of major fimbrial proteins of Porphyromonas gingivalis.

Authors:  J Y Lee; H T Sojar; A Amano; R J Genco
Journal:  Protein Expr Purif       Date:  1995-08       Impact factor: 1.650

10.  Structural domains of Porphyromonas gingivalis recombinant fimbrillin that mediate binding to salivary proline-rich protein and statherin.

Authors:  A Amano; A Sharma; J Y Lee; H T Sojar; P A Raj; R J Genco
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more
  4 in total

1.  M cell-targeting ligand and consensus dengue virus envelope protein domain III fusion protein production in transgenic rice calli.

Authors:  Tae-Geum Kim; Mi-Young Kim; Nguyen-Xuan Huy; Sae-Hae Kim; Moon-Sik Yang
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

2.  The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity.

Authors:  Deana N Toussi; Xiuping Liu; Paola Massari
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

3.  Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes.

Authors:  Mi-Young Kim; Byeong-Young Kim; Sun-Mi Oh; Rajko Reljic; Yong-Suk Jang; Moon-Sik Yang
Journal:  Plant Mol Biol       Date:  2016-08-26       Impact factor: 4.076

Review 4.  Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities.

Authors:  Victor Vaernewyck; Boaz Arzi; Niek N Sanders; Eric Cox; Bert Devriendt
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.